

ICMJE DISCLOSURE FORM

Date: 17/09/2024

Your Name: Simon Timothy Abrams

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div> <div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div> <input type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90				Click the tab key to add additional rows.
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div> <div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						
3	<div> <div>Royalties or licenses</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 21/10/24

Your Name: Dr Gayatri Amirthalingam

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
Time frame: Since the initial planning of the work										
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90						
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90									
Time frame: past 36 months										
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>								
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>								

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 20px;"></td><td style="width: 50%; height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 20px;"></td><td style="width: 50%; height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 20px;"></td><td style="width: 50%; height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 06/09/2024

Your Name: Kevin Brown

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div> <div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div> <input type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90				Click the tab key to add additional rows.
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div> <div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						
3	<div> <div>Royalties or licenses</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 4/9/2024

Your Name: Richard J Buka

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
Time frame: Since the initial planning of the work											
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;">National Institute for Health Research</td> <td style="width: 50%; padding: 5px;">NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90.</td> </tr> <tr> <td style="height: 20px;"></td> <td></td> </tr> <tr> <td colspan="2" style="text-align: center; padding: 5px;">Click the tab key to add additional rows.</td> </tr> </table>		National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90.			Click the tab key to add additional rows.			
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90.										
Click the tab key to add additional rows.											
Time frame: past 36 months											
2	Grants or contracts from any entity (if not indicated in item #1 above).	<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;">University of Birmingham Research Development Fund</td> <td style="width: 50%; padding: 5px;">PI. Prevention Of Portal vein thrombosis with Btk inhibitors (The POP-Btk Study). £300</td> </tr> <tr> <td style="padding: 5px;">British Heart Foundation</td> <td style="padding: 5px;">Co-I. The molecular basis of variation in response to platelet activation by FcγRIIA: Implications for the risk of thrombosis. £236,336</td> </tr> <tr> <td style="padding: 5px;">AstraZeneca</td> <td style="padding: 5px;">PI. A HaemSTAR-led UK national audit of the use of Reversal Agents in Patients anticoagulated with Direct Oral anticoagulants. £88,000</td> </tr> <tr> <td style="padding: 5px;">British Heart Foundation</td> <td style="padding: 5px;">Accelerator Award (UoB: AA/18/2/34218) and BHF Scholarship for salary.</td> </tr> </table>		University of Birmingham Research Development Fund	PI. Prevention Of Portal vein thrombosis with Btk inhibitors (The POP-Btk Study). £300	British Heart Foundation	Co-I. The molecular basis of variation in response to platelet activation by FcγRIIA: Implications for the risk of thrombosis. £236,336	AstraZeneca	PI. A HaemSTAR-led UK national audit of the use of Reversal Agents in Patients anticoagulated with Direct Oral anticoagulants. £88,000	British Heart Foundation	Accelerator Award (UoB: AA/18/2/34218) and BHF Scholarship for salary.
University of Birmingham Research Development Fund	PI. Prevention Of Portal vein thrombosis with Btk inhibitors (The POP-Btk Study). £300										
British Heart Foundation	Co-I. The molecular basis of variation in response to platelet activation by FcγRIIA: Implications for the risk of thrombosis. £236,336										
AstraZeneca	PI. A HaemSTAR-led UK national audit of the use of Reversal Agents in Patients anticoagulated with Direct Oral anticoagulants. £88,000										
British Heart Foundation	Accelerator Award (UoB: AA/18/2/34218) and BHF Scholarship for salary.										

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)																
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																	
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None <table border="1"> <tr><td>Bayer</td><td>Honoraria</td></tr> <tr><td>Sanofi</td><td>Consultancy</td></tr> <tr><td>Sobi</td><td>Honoraria and consultancy</td></tr> <tr><td>Viartis</td><td>Honoraria</td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Bayer	Honoraria	Sanofi	Consultancy	Sobi	Honoraria and consultancy	Viartis	Honoraria								
Bayer	Honoraria																		
Sanofi	Consultancy																		
Sobi	Honoraria and consultancy																		
Viartis	Honoraria																		
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																	
7	Support for attending meetings and/or travel	<input type="checkbox"/> None <table border="1"> <tr><td></td><td>Conference Fee for ESBMT 2012.</td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>			Conference Fee for ESBMT 2012.														
	Conference Fee for ESBMT 2012.																		
8	Patents planned, issued or pending	<input type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																	
10	Leadership or fiduciary role in other board,	<input type="checkbox"/> None <table border="1"> <tr><td>HaemSTAR</td><td>Trustee, Chair 2022-Present)</td></tr> </table>		HaemSTAR	Trustee, Chair 2022-Present)														
HaemSTAR	Trustee, Chair 2022-Present)																		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
	society, committee or advocacy group, paid or unpaid	<table border="1"> <tr> <td>Smartemis Limited</td> <td>Director</td> </tr> <tr> <td>P2B Property Limited</td> <td>Director</td> </tr> </table>	Smartemis Limited	Director	P2B Property Limited	Director			
Smartemis Limited	Director								
P2B Property Limited	Director								
11	Stock or stock options	<input type="checkbox"/> None <table border="1"> <tr> <td>Exelixis</td> <td>£1320</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		Exelixis	£1320				
Exelixis	£1320								
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>							
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>									

ICMJE DISCLOSURE FORM

Date: 19/09/2024

Your Name: Professor Sir Mark Caulfield

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
Time frame: Since the initial planning of the work										
1	<input type="checkbox"/> None <table border="1"> <tr> <td>NIHR</td> <td></td> </tr> <tr> <td>Genomics England Limited</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	NIHR		Genomics England Limited						
NIHR										
Genomics England Limited										
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.									
Time frame: past 36 months										
2	<input type="checkbox"/> None <table border="1"> <tr> <td>NIHR BRC & Barts BioResource</td> <td>£21,194,785</td> </tr> <tr> <td>British Heart Foundation (BHF)</td> <td>£10,000,000 for 5 years for the BHF Data Science Centre (SP/19/3/34678)</td> </tr> <tr> <td>UK Research and Innovation</td> <td>Data and Connectivity National Core Study led by Health Data Research UK in partnership with the Office for National Statistics (grant reference MC_PC_20058)</td> </tr> <tr> <td>UK Research and Innovation</td> <td>Longitudinal Health and Wellbeing COVID-19 National Core Study, which was established by the UK Chief Scientific Officer in October 2020 (grant references MC_PC_20030 and MC_PC_20059)</td> </tr> </table>	NIHR BRC & Barts BioResource	£21,194,785	British Heart Foundation (BHF)	£10,000,000 for 5 years for the BHF Data Science Centre (SP/19/3/34678)	UK Research and Innovation	Data and Connectivity National Core Study led by Health Data Research UK in partnership with the Office for National Statistics (grant reference MC_PC_20058)	UK Research and Innovation	Longitudinal Health and Wellbeing COVID-19 National Core Study, which was established by the UK Chief Scientific Officer in October 2020 (grant references MC_PC_20030 and MC_PC_20059)	
NIHR BRC & Barts BioResource	£21,194,785									
British Heart Foundation (BHF)	£10,000,000 for 5 years for the BHF Data Science Centre (SP/19/3/34678)									
UK Research and Innovation	Data and Connectivity National Core Study led by Health Data Research UK in partnership with the Office for National Statistics (grant reference MC_PC_20058)									
UK Research and Innovation	Longitudinal Health and Wellbeing COVID-19 National Core Study, which was established by the UK Chief Scientific Officer in October 2020 (grant references MC_PC_20030 and MC_PC_20059)									
	Grants or contracts from any entity (if not indicated in item #1 above).									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board,	<input type="checkbox"/> None									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)																								
	society, committee or advocacy group, paid or unpaid	<table border="1"> <tr> <td>President and Trustee of the British Pharmacological Society</td> <td>Unpaid</td> </tr> <tr> <td>Non-Executive Director (QMUL representation of Barts Health Board)</td> <td>£13000 per annum</td> </tr> <tr> <td>(CGEN) Canadian Genomes Platform Board Member</td> <td>Unpaid</td> </tr> <tr> <td>Director of the NIHR BRC & Barts BioResource</td> <td>Unpaid</td> </tr> <tr> <td>Non-Executive Director for the MedCity Board</td> <td>Unpaid</td> </tr> <tr> <td>Board Member Barts Charity Committee</td> <td>Unpaid</td> </tr> <tr> <td>Co-Chair Barts/QMUL Joint Clinical Research Board</td> <td>Unpaid</td> </tr> <tr> <td>Member Medical Schools Council</td> <td>Unpaid</td> </tr> <tr> <td>UCLP Board Member</td> <td>Unpaid</td> </tr> <tr> <td>QMUL Civic Advisory Board</td> <td>Unpaid</td> </tr> <tr> <td>QMUL Council</td> <td>Unpaid</td> </tr> <tr> <td>QMUL Life Sciences Steering Group</td> <td>Unpaid</td> </tr> </table>	President and Trustee of the British Pharmacological Society	Unpaid	Non-Executive Director (QMUL representation of Barts Health Board)	£13000 per annum	(CGEN) Canadian Genomes Platform Board Member	Unpaid	Director of the NIHR BRC & Barts BioResource	Unpaid	Non-Executive Director for the MedCity Board	Unpaid	Board Member Barts Charity Committee	Unpaid	Co-Chair Barts/QMUL Joint Clinical Research Board	Unpaid	Member Medical Schools Council	Unpaid	UCLP Board Member	Unpaid	QMUL Civic Advisory Board	Unpaid	QMUL Council	Unpaid	QMUL Life Sciences Steering Group	Unpaid	
President and Trustee of the British Pharmacological Society	Unpaid																										
Non-Executive Director (QMUL representation of Barts Health Board)	£13000 per annum																										
(CGEN) Canadian Genomes Platform Board Member	Unpaid																										
Director of the NIHR BRC & Barts BioResource	Unpaid																										
Non-Executive Director for the MedCity Board	Unpaid																										
Board Member Barts Charity Committee	Unpaid																										
Co-Chair Barts/QMUL Joint Clinical Research Board	Unpaid																										
Member Medical Schools Council	Unpaid																										
UCLP Board Member	Unpaid																										
QMUL Civic Advisory Board	Unpaid																										
QMUL Council	Unpaid																										
QMUL Life Sciences Steering Group	Unpaid																										
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																									
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																									
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																									
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>																											

ICMJE DISCLOSURE FORM

Date: 05/09/2024

Your Name: Joshua Gardner

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div> <div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div> <input type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90				Click the tab key to add additional rows.
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div> <div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						
3	<div> <div>Royalties or licenses</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 04/09/2024

Your Name: David Goldblatt

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div style="display: flex; align-items: flex-start;"> <div style="flex: 1;"> <p>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)</p> <p>No time limit for this item.</p> </div> <div style="flex: 2; padding-left: 10px;"> <div style="display: flex; align-items: center; margin-bottom: 10px;"> <input checked="" type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;">National Institute for Health Research</td> <td style="width: 50%; padding: 5px;">NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td style="height: 20px;"></td> <td></td> </tr> <tr> <td style="height: 20px;"></td> <td></td> </tr> </table> </div> </div>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90					
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
Time frame: past 36 months								
2	<div style="display: flex; align-items: flex-start;"> <div style="flex: 1;"> <p>Grants or contracts from any entity (if not indicated in item #1 above).</p> </div> <div style="flex: 2; padding-left: 10px;"> <div style="display: flex; align-items: center; margin-bottom: 10px;"> <input checked="" type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 20px;"></td><td style="width: 50%;"></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table> </div> </div>							
3	<div style="display: flex; align-items: flex-start;"> <div style="flex: 1;"> <p>Royalties or licenses</p> </div> <div style="flex: 2; padding-left: 10px;"> <div style="display: flex; align-items: center; margin-bottom: 10px;"> <input checked="" type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 20px;"></td><td style="width: 50%;"></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table> </div> </div>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 4.9.24

Your Name: Charlotte Lovatt

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div> <input type="checkbox"/> None </div> <table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90				Click the tab key to add additional rows.	
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div> <input checked="" type="checkbox"/> None </div> <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>							
3	<div> <input checked="" type="checkbox"/> None </div> <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 04/09/2024

Your Name: Samantha Montague

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<div style="border: 1px solid black; padding: 5px;"> <input checked="" type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <td style="width: 50%; padding: 2px;">National Institute for Health Research</td> <td style="width: 50%; padding: 2px;">NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td style="height: 20px;"></td> <td></td> </tr> <tr> <td colspan="2" style="text-align: center; font-size: small;">Click the tab key to add additional rows.</td> </tr> </table>		National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90			Click the tab key to add additional rows.	
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90								
Click the tab key to add additional rows.									
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	<div style="border: 1px solid black; padding: 5px;"> <input type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <td style="width: 50%; padding: 2px;">British Heart Foundation project grant (PG/22/11230)</td> <td style="width: 50%; padding: 2px;">Molecular basis of variation in response to platelet activation by FcγRIIA: implications for risk of thrombosis</td> </tr> <tr> <td style="padding: 2px;">British Heart Foundation Accelerator (BHF) (AA/18/2/34218)</td> <td></td> </tr> <tr> <td style="height: 20px;"></td> <td></td> </tr> </table>		British Heart Foundation project grant (PG/22/11230)	Molecular basis of variation in response to platelet activation by FcγRIIA: implications for risk of thrombosis	British Heart Foundation Accelerator (BHF) (AA/18/2/34218)			
British Heart Foundation project grant (PG/22/11230)	Molecular basis of variation in response to platelet activation by FcγRIIA: implications for risk of thrombosis								
British Heart Foundation Accelerator (BHF) (AA/18/2/34218)									
3	Royalties or licenses	<div style="border: 1px solid black; padding: 5px;"> <input checked="" type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 05/09/2024

Your Name: Dean J Naisbitt

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div> <div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div> <input type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90				Click the tab key to add additional rows.
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div> <div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						
3	<div> <div>Royalties or licenses</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None <table border="1"> <tr> <td>ARDAT consortium</td> <td>Member of the consortium (www.ardat.org)</td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>	ARDAT consortium	Member of the consortium (www.ardat.org)							
ARDAT consortium	Member of the consortium (www.ardat.org)										

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 9/3/2024

Your Name: Phillip LR Nicolson

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
Time frame: Since the initial planning of the work											
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;">National Institute for Health Research</td> <td style="width: 50%; padding: 5px;">NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90.</td> </tr> <tr> <td style="height: 20px;"></td> <td></td> </tr> <tr> <td colspan="2" style="text-align: center; padding: 5px;">Click the tab key to add additional rows.</td> </tr> </table>		National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90.			Click the tab key to add additional rows.			
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90.										
Click the tab key to add additional rows.											
Time frame: past 36 months											
2	Grants or contracts from any entity (if not indicated in item #1 above).	<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;">Birmingham Health Partners</td> <td style="width: 50%; padding: 5px;">Co-PI. Starter Fellowship (For Eman Hassan). The effect of tyrosine kinase inhibitors and CLEC-2 biologics on haem-induced platelet activation and thrombosis in blood from sickle cell patients. £143,447</td> </tr> <tr> <td style="padding: 5px;">University of Birmingham Research Development Fund</td> <td style="padding: 5px;">PI. Prevention Of Portal vein thrombosis with Btk inhibitors (The POP-Btk Study). £300</td> </tr> <tr> <td style="padding: 5px;">British Heart Foundation</td> <td style="padding: 5px;">Co-I. The molecular basis of variation in response to platelet activation by FcγRIIA: Implications for the risk of thrombosis. £236,336</td> </tr> <tr> <td style="padding: 5px;">Acticor Biotech</td> <td style="padding: 5px;">Co-I. LIBERATE: A phase IIb, randomised, double-blinded, placebo-controlled trial To</td> </tr> </table>		Birmingham Health Partners	Co-PI. Starter Fellowship (For Eman Hassan). The effect of tyrosine kinase inhibitors and CLEC-2 biologics on haem-induced platelet activation and thrombosis in blood from sickle cell patients. £143,447	University of Birmingham Research Development Fund	PI. Prevention Of Portal vein thrombosis with Btk inhibitors (The POP-Btk Study). £300	British Heart Foundation	Co-I. The molecular basis of variation in response to platelet activation by FcγRIIA: Implications for the risk of thrombosis. £236,336	Acticor Biotech	Co-I. LIBERATE: A phase IIb, randomised, double-blinded, placebo-controlled trial To
Birmingham Health Partners	Co-PI. Starter Fellowship (For Eman Hassan). The effect of tyrosine kinase inhibitors and CLEC-2 biologics on haem-induced platelet activation and thrombosis in blood from sickle cell patients. £143,447										
University of Birmingham Research Development Fund	PI. Prevention Of Portal vein thrombosis with Btk inhibitors (The POP-Btk Study). £300										
British Heart Foundation	Co-I. The molecular basis of variation in response to platelet activation by FcγRIIA: Implications for the risk of thrombosis. £236,336										
Acticor Biotech	Co-I. LIBERATE: A phase IIb, randomised, double-blinded, placebo-controlled trial To										

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)																
		investigate the safety, efficacy and mechanism of inhibiting platelet GPVI as a treatment for ST-elevation myocardial infarction. £1,277,699																
	AstraZeneca	PI. A HaemSTAR-led UK national audit of the use of Reversal Agents in Patients anticoagulated with Direct Oral anticoagulants. £88,000																
	British Heart Foundation	PI. Accelerator Award: BAT-X: Bleeding Assessment Tool In X-Linked Agammaglobulinaemia. £12,719																
	Sanofi S.A	PI. The effect of Btk inhibition on platelet activation and Thrombosis (focussing on hepatic portal vein thrombosis). £73,213																
	University of Birmingham Dynamic Investment Fund	PI. BAT-X: Bleeding Assessment Tool In X-Linked Agammaglobulinaemia. £15,213																
	Wellcome Trust Translational Discovery Fund	Co-I. Stability, PK and efficacy studies on a humanised CLEC-2 Fab. £23,101																
	Principia Biopharma	PI. The effect of Btk inhibition on platelet activation and Thrombosis (focussing on hepatic portal vein thrombosis). £163,000																
	BHF Accelerator Award	Investigating Mechanisms of VITT. £2,500																
	Rigel	Co-I: Targeting GPVI and CLEC-2 with fostamatinib as a novel antithrombotic strategy. £43,400																
	Novartis	PI: Selective Btk inhibition and platelet biology. £70,500																
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None <table border="1"> <tr><td>Bayer</td><td>28/02/2020. £900</td></tr> <tr><td>Takeda</td><td>14/07/2021. £357.50</td></tr> <tr><td>Grifols</td><td>25/08/2021. £1,650</td></tr> <tr><td>Sobi</td><td>29/10/2021. £1,563</td></tr> <tr><td>Sobi</td><td>06/03/2024. £1,120</td></tr> <tr><td>Hartley Taylor</td><td>15/05/2024. £500</td></tr> <tr><td>Sobi</td><td>19/06/2024. £2,100</td></tr> <tr><td>Sobi</td><td>29/8/2024. £280</td></tr> </table>	Bayer	28/02/2020. £900	Takeda	14/07/2021. £357.50	Grifols	25/08/2021. £1,650	Sobi	29/10/2021. £1,563	Sobi	06/03/2024. £1,120	Hartley Taylor	15/05/2024. £500	Sobi	19/06/2024. £2,100	Sobi	29/8/2024. £280
Bayer	28/02/2020. £900																	
Takeda	14/07/2021. £357.50																	
Grifols	25/08/2021. £1,650																	
Sobi	29/10/2021. £1,563																	
Sobi	06/03/2024. £1,120																	
Hartley Taylor	15/05/2024. £500																	
Sobi	19/06/2024. £2,100																	
Sobi	29/8/2024. £280																	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
7	Support for attending meetings and/or travel	<input type="checkbox"/> None <table border="1"> <tr> <td>Chugai</td> <td>Conference Fee for ESBMT 2012.</td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Chugai	Conference Fee for ESBMT 2012.				
Chugai	Conference Fee for ESBMT 2012.								
8	Patents planned, issued or pending	<input type="checkbox"/> None <table border="1"> <tr> <td>US Patent Application (US20240207277A1). With Christopher W Smith, Steve P Watson and Claire Langrish</td> <td>Methods For Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds. Issued 27/6/2024.</td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		US Patent Application (US20240207277A1). With Christopher W Smith, Steve P Watson and Claire Langrish	Methods For Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds. Issued 27/6/2024.				
US Patent Application (US20240207277A1). With Christopher W Smith, Steve P Watson and Claire Langrish	Methods For Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds. Issued 27/6/2024.								
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None <table border="1"> <tr> <td>HaemSTAR</td> <td>Trustee, Treasurer, Previous Chair (unpaid, 2017-Present)</td> </tr> <tr> <td>British Society of Haematology Grants Committee</td> <td>Committee Member (unpaid, 2018-2024)</td> </tr> <tr><td></td><td></td></tr> </table>		HaemSTAR	Trustee, Treasurer, Previous Chair (unpaid, 2017-Present)	British Society of Haematology Grants Committee	Committee Member (unpaid, 2018-2024)		
HaemSTAR	Trustee, Treasurer, Previous Chair (unpaid, 2017-Present)								
British Society of Haematology Grants Committee	Committee Member (unpaid, 2018-2024)								
11	Stock or stock options	<input type="checkbox"/> None <table border="1"> <tr> <td>Sanofi SA</td> <td>£87.43</td> </tr> <tr> <td>Swedish Orphan Biovitrium AB</td> <td>£208.86</td> </tr> <tr><td></td><td></td></tr> </table>		Sanofi SA	£87.43	Swedish Orphan Biovitrium AB	£208.86		
Sanofi SA	£87.43								
Swedish Orphan Biovitrium AB	£208.86								
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date: 04 SEPT 2024

Your Name: Alan Parker

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<input type="checkbox"/> None							
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90				Click the tab key to add additional rows.	
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<input checked="" type="checkbox"/> None							
Grants or contracts from any entity (if not indicated in item #1 above).	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>							
3	<input checked="" type="checkbox"/> None							
Royalties or licenses	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr> <td>Trocept Therapeutics</td> <td>Founder and Chief Scientific Officer</td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Trocept Therapeutics	Founder and Chief Scientific Officer				
Trocept Therapeutics	Founder and Chief Scientific Officer								

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 06/09/2024

Your Name: Sue Pavord

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div> <div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div> <input type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90				Click the tab key to add additional rows.
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div> <div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						
3	<div> <div>Royalties or licenses</div> <div> <input type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td>Cambridge University Press</td> <td>Royalties received personally for The Obstetric Haematology Manual</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	Cambridge University Press	Royalties received personally for The Obstetric Haematology Manual				
Cambridge University Press	Royalties received personally for The Obstetric Haematology Manual							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	<input checked="" type="checkbox"/> None	
		Payments for advice or advisory boards, received from SOBI and Janssen	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
		Fees for educational lectures received from SOBI, Amgen, Janssen, Novartis, Pharmacosmos	Personal payments
		Sponsorship of £600 for the running of Haematology in Obstetrics course from Octapharma, Pharmacosmos, LFB, Haemonetics	Payments direct to course venue St Edmund Hall
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
		Butcher & Barlow £662	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
		President of British Society for Haematology	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None	
		Ely Lilly	£1541
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/>	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date: 05/09/2024

Your Name: Munir Pirmohamed

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div style="margin-bottom: 5px;"><input type="checkbox"/> None</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td colspan="2" style="text-align: center; font-size: small;">Click the tab key to add additional rows.</td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90			Click the tab key to add additional rows.		
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
Click the tab key to add additional rows.								
Time frame: past 36 months								
2	<div style="margin-bottom: 5px;"><input type="checkbox"/> None</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">MRC Medicines Development Fellowship</td> <td>Grant for training of medical fellows (£8.2 million) jointly between University of Liverpool, University of Manchester, QMUL and University of Glasgow. Funding to the Universities from MRC, GSK, AZ, Hammersmith Medicines Research and Optum.</td> </tr> <tr> <td>ESRC</td> <td>Grant (£854,505) to the University of Liverpool and University of Manchester on: The organisation and diffusion of translational research: Can cardiovascular medicine learn from oncology? Case studies of pharmacogenomics in the NHS</td> </tr> </table>	MRC Medicines Development Fellowship	Grant for training of medical fellows (£8.2 million) jointly between University of Liverpool, University of Manchester, QMUL and University of Glasgow. Funding to the Universities from MRC, GSK, AZ, Hammersmith Medicines Research and Optum.	ESRC	Grant (£854,505) to the University of Liverpool and University of Manchester on: The organisation and diffusion of translational research: Can cardiovascular medicine learn from oncology? Case studies of pharmacogenomics in the NHS			
MRC Medicines Development Fellowship	Grant for training of medical fellows (£8.2 million) jointly between University of Liverpool, University of Manchester, QMUL and University of Glasgow. Funding to the Universities from MRC, GSK, AZ, Hammersmith Medicines Research and Optum.							
ESRC	Grant (£854,505) to the University of Liverpool and University of Manchester on: The organisation and diffusion of translational research: Can cardiovascular medicine learn from oncology? Case studies of pharmacogenomics in the NHS							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		MRC	Co-applicant on a grant (£203,257) led by Makerere University in Uganda (all funding to Uganda) on "Two-way risk communication mobile application versus traditional methods of adverse drug reaction reporting in Uganda: a randomized controlled trial"
		MRC	Grant for African Research Leader programme for Dr Ronald Kiguba (£749,995) – all funding going to Makerere University and University of Liverpool.
		NHS Genomics Unit	Grant to University of Liverpool as part of the NW Genomic Medicine Service Alliance
		MRC	Grant to University of Liverpool (£795,534) on "A personalised approach to manage adverse reactions to CFTR modulator therapy in patients with cystic fibrosis."
		NHS Race and Health Observatory	Grant to the University of Liverpool (£260,650) entitled "Improving the utility of dihydropyrimidine dehydrogenase genetic testing in the NHS".
		Health Data Research UK	Grant to the University of Liverpool for £5.5 million for the Medicines in Acute and Chronic care driver programme
		MRC	Equipment Grant to the University of Liverpool (£152,544) for "Provision of a MassArray Mass-spectrometry based multiplex genotyping platform (Agena Biosciences)."
		NIHR	Grant to the Universities of Leeds and Liverpool (£1,016,223) for "Optimising structured medication reviews for older people with severe frailty and care home residents to reduce overprescribing and associated inequalities"
		NIHR Program Grant	Grant (£2,527,221) to the Universities of Liverpool, Manchester, Bangor on "Personalising renal function monitoring and interventions in people living with heart failure: RENAL-HF"
		NIHR HTA	Grant to the University of Liverpool and Liverpool University Hospital Foundation Trust for £1,558,377 to undertake a trial (An adaptive-design randomised placebo-controlled trial of baclofen in the treatment of alcohol use disorder in patients with liver cirrhosis (BASIS))
		EU Innovative Medicines Initiative	Grant to University of Liverpool and multiple other organizations (see www.ardat.org) from the EU Commission for ARDAT (accelerating research and development for advanced therapies) – 25 million euros
		Innovate UK	Grant (£50,000) to University of Liverpool and British Pharmacological Society for the creation of a UK Regulatory Science and Innovation Network in Pharmacogenomics.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		MRC	Partnership funding for the MRC Clinical Pharmacology Training Scheme (co-funded by MRC, Roche, UCB, Eli Lilly & Novartis)
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety	<input type="checkbox"/> None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
	Monitoring Board or Advisory Board	<table border="1"> <tr> <td>Advisory Board Chair</td> <td>Bosch Health Foundation, Stuttgart, Germany</td> </tr> <tr> <td>Vice Chair</td> <td>Qatar Precision Health Initiative</td> </tr> <tr> <td></td> <td></td> </tr> </table>	Advisory Board Chair	Bosch Health Foundation, Stuttgart, Germany	Vice Chair	Qatar Precision Health Initiative					
Advisory Board Chair	Bosch Health Foundation, Stuttgart, Germany										
Vice Chair	Qatar Precision Health Initiative										
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None <table border="1"> <tr> <td>Chair</td> <td>Commission on Human Medicines</td> </tr> <tr> <td>Medical Trustee</td> <td>British Heart Foundation</td> </tr> <tr> <td>Council Member</td> <td>Medical Research Council</td> </tr> <tr> <td>ARDAT consortium</td> <td>Member of the consortium (www.ardat.org)</td> </tr> </table>		Chair	Commission on Human Medicines	Medical Trustee	British Heart Foundation	Council Member	Medical Research Council	ARDAT consortium	Member of the consortium (www.ardat.org)
Chair	Commission on Human Medicines										
Medical Trustee	British Heart Foundation										
Council Member	Medical Research Council										
ARDAT consortium	Member of the consortium (www.ardat.org)										
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>									
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>									
13	Other financial or non-financial interests	<input type="checkbox"/> <table border="1"> <tr> <td>MC Diagnostics</td> <td>Has developed an HLA genotyping panel with MC Diagnostics but does not benefit financially from this.</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		MC Diagnostics	Has developed an HLA genotyping panel with MC Diagnostics but does not benefit financially from this.						
MC Diagnostics	Has developed an HLA genotyping panel with MC Diagnostics but does not benefit financially from this.										

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 05/09/2024

Your Name: Mary Ramsay

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div> <div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div> <input type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90				Click the tab key to add additional rows.
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div> <div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						
3	<div> <div>Royalties or licenses</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> <table border="1"> <tr> <td>Pfizer</td> <td>Pfizer, My directorate at UKHSA has provided vaccine manufacturers with post-marketing surveillance reports on meningococcal, Haemophilus influenzae, and pneumococcal infections, which the companies are required to submit to the UK Licensing Authority in compliance with their risk management strategy. A cost recovery charge is made for these reports.</td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Pfizer	Pfizer, My directorate at UKHSA has provided vaccine manufacturers with post-marketing surveillance reports on meningococcal, Haemophilus influenzae, and pneumococcal infections, which the companies are required to submit to the UK Licensing Authority in compliance with their risk management strategy. A cost recovery charge is made for these reports.				
Pfizer	Pfizer, My directorate at UKHSA has provided vaccine manufacturers with post-marketing surveillance reports on meningococcal, Haemophilus influenzae, and pneumococcal infections, which the companies are required to submit to the UK Licensing Authority in compliance with their risk management strategy. A cost recovery charge is made for these reports.								

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 17/09/2024

Your Name: Prof Jonathan A C Sterne

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
Time frame: Since the initial planning of the work										
1	<div> <div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div> <input type="checkbox"/> None </div> </div> <table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines</td> </tr> <tr> <td>UKRI MRC</td> <td>Longitudinal Health and Wellbeing National Core Study</td> </tr> <tr> <td>MRC and multiple partner funders</td> <td>Core funding to Health Data Research UK</td> </tr> <tr> <td></td> <td></td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines	UKRI MRC	Longitudinal Health and Wellbeing National Core Study	MRC and multiple partner funders	Core funding to Health Data Research UK			
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines									
UKRI MRC	Longitudinal Health and Wellbeing National Core Study									
MRC and multiple partner funders	Core funding to Health Data Research UK									
Time frame: past 36 months										
2	<div> <div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div> <input checked="" type="checkbox"/> None </div> </div> <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>									
3	<div> <div>Royalties or licenses</div> <div> <input checked="" type="checkbox"/> None </div> </div> <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date: 17/09/2024

Your Name: Prof Cathie LM Sudlow

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
Time frame: Since the initial planning of the work										
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div> <input type="checkbox"/> None </div> <table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td>BHF</td> <td>BHF Data Science Centre award to Health Data Research UK. £11 million Jan 2020-June 2025</td> </tr> <tr> <td>MRC and multiple partner funders</td> <td>Core funding to Health Data Research UK. £72 million April 2023-March 2028</td> </tr> <tr> <td></td> <td></td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90	BHF	BHF Data Science Centre award to Health Data Research UK. £11 million Jan 2020-June 2025	MRC and multiple partner funders	Core funding to Health Data Research UK. £72 million April 2023-March 2028			
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90									
BHF	BHF Data Science Centre award to Health Data Research UK. £11 million Jan 2020-June 2025									
MRC and multiple partner funders	Core funding to Health Data Research UK. £72 million April 2023-March 2028									
Time frame: past 36 months										
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div> <input checked="" type="checkbox"/> None </div> <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
3	<div>Royalties or licenses</div> <div> <input checked="" type="checkbox"/> None </div> <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date: 05/09/2024

Your Name: Cheng-Hock Toh

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div> <div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div> <input type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90				Click the tab key to add additional rows.
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div> <div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						
3	<div> <div>Royalties or licenses</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 17/09/2024

Your Name: Guozheng Wang

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div> <div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div> <input type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td>National Institute for Health Research</td> <td>NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90				Click the tab key to add additional rows.
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	<div> <div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						
3	<div> <div>Royalties or licenses</div> <div> <input checked="" type="checkbox"/> None </div> </div>	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 04/09/2024

Your Name: Steve Watson

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None							
	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">National Institute for Health Research</td><td style="width: 50%;">NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td></tr> <tr> <td> </td><td> </td></tr> <tr> <td> </td><td>Click the tab key to add additional rows.</td></tr> </table>	National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90				Click the tab key to add additional rows.	
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90							
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2 Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None							
	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">British Heart Foundation project grant (PG/22/11230)</td><td style="width: 50%;">Molecular basis of variation in response to platelet activation by FcγRIIA: implications for risk of thrombosis</td></tr> <tr> <td>British Heart Foundation Chair renewal (CH03/003) (2022-24)</td><td> </td></tr> <tr> <td>MRC IAA</td><td>Development of a bivalent nanobody to GPVI and human albumin as a novel anti-thrombotic therapy</td></tr> </table>	British Heart Foundation project grant (PG/22/11230)	Molecular basis of variation in response to platelet activation by FcγRIIA: implications for risk of thrombosis	British Heart Foundation Chair renewal (CH03/003) (2022-24)		MRC IAA	Development of a bivalent nanobody to GPVI and human albumin as a novel anti-thrombotic therapy	
British Heart Foundation project grant (PG/22/11230)	Molecular basis of variation in response to platelet activation by FcγRIIA: implications for risk of thrombosis							
British Heart Foundation Chair renewal (CH03/003) (2022-24)								
MRC IAA	Development of a bivalent nanobody to GPVI and human albumin as a novel anti-thrombotic therapy							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board,	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
	society, committee or advocacy group, paid or unpaid	<table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 04/09/2024

Your Name: William Whiteley

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)										
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<div style="border: 1px solid black; padding: 5px;"> <input type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <td style="width: 50%;">National Institute for Health Research</td> <td style="width: 50%;">NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90</td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td colspan="2" style="text-align: center;">Click the tab key to add additional rows.</td> </tr> </table>		National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90			Click the tab key to add additional rows.					
National Institute for Health Research	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90												
Click the tab key to add additional rows.													
2	Grants or contracts from any entity (if not indicated in item #1 above).	<div style="border: 1px solid black; padding: 5px;"> <input type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <td style="width: 50%;">Neurii</td> <td style="width: 50%;">Grant from Eisai, Gates, LifeArc</td> </tr> <tr> <td>ADDI</td> <td>Brain Health Data Pilot</td> </tr> <tr> <td>Alzheimer's Association</td> <td>Training partnership, brain vascular disease</td> </tr> <tr> <td>CSO</td> <td>RedUcing risk of stroke and demeNtia in patients with COVert cERebrovascular disease: a pilot and development study (UNCOVER)</td> </tr> <tr> <td>BHF Data Science Centre</td> <td>: British Burden of CVD</td> </tr> </table>		Neurii	Grant from Eisai, Gates, LifeArc	ADDI	Brain Health Data Pilot	Alzheimer's Association	Training partnership, brain vascular disease	CSO	RedUcing risk of stroke and demeNtia in patients with COVert cERebrovascular disease: a pilot and development study (UNCOVER)	BHF Data Science Centre	: British Burden of CVD
Neurii	Grant from Eisai, Gates, LifeArc												
ADDI	Brain Health Data Pilot												
Alzheimer's Association	Training partnership, brain vascular disease												
CSO	RedUcing risk of stroke and demeNtia in patients with COVert cERebrovascular disease: a pilot and development study (UNCOVER)												
BHF Data Science Centre	: British Burden of CVD												

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
4	Consulting fees	<input type="checkbox"/> None <table border="1"> <tr> <td>Viatrix</td> <td>Advisory Board, fees to university</td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>	Viatrix	Advisory Board, fees to university							
Viatrix	Advisory Board, fees to university										
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input type="checkbox"/> None <table border="1"> <tr> <td>Independent witness to court</td> <td></td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>	Independent witness to court								
Independent witness to court											
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> None <table border="1"> <tr> <td>Multiple academic trials DMC</td> <td>Unenumerated</td> </tr> <tr> <td>UKHSA</td> <td>Immunisation and Vaccine Preventable Diseases Division of the UKHSA has provided vaccine manufacturers (including Pfizer) with post-marketing surveillance reports on pneumococcal and meningococcal infection which the companies are required to submit to the UK</td> </tr> </table>	Multiple academic trials DMC	Unenumerated	UKHSA	Immunisation and Vaccine Preventable Diseases Division of the UKHSA has provided vaccine manufacturers (including Pfizer) with post-marketing surveillance reports on pneumococcal and meningococcal infection which the companies are required to submit to the UK					
Multiple academic trials DMC	Unenumerated										
UKHSA	Immunisation and Vaccine Preventable Diseases Division of the UKHSA has provided vaccine manufacturers (including Pfizer) with post-marketing surveillance reports on pneumococcal and meningococcal infection which the companies are required to submit to the UK										

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports.
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date: 9/3/2024

Your Name: Angela M Wood

Manuscript Title: Understanding Mechanisms of Thrombosis and Thrombocytopenia with Adenoviral SARS-CoV-2 Vaccines: A Comprehensive Synopsis

Manuscript Number (if known): EME NIHR135073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)																				
Time frame: Since the initial planning of the work																							
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;">National Institute for Health Research (NIHR)</td> <td style="width: 50%; padding: 5px;">NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90.</td> </tr> <tr> <td style="height: 20px;"></td> <td></td> </tr> <tr> <td colspan="2" style="text-align: center; padding: 5px;">Click the tab key to add additional rows.</td> </tr> </table>		National Institute for Health Research (NIHR)	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90.			Click the tab key to add additional rows.															
National Institute for Health Research (NIHR)	NIHR135073. Understanding Mechanisms of Thrombosis and Thrombocytopenia in COVID-19 and with SARS-CoV-2 Vaccines. £1,669,962.90.																						
Click the tab key to add additional rows.																							
Time frame: past 36 months																							
2	Grants or contracts from any entity (if not indicated in item #1 above).	<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input type="checkbox"/> None </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;">HDR UK</td> <td style="width: 50%; padding: 5px;">10% secondment to the BHF Data Science Centre</td> </tr> <tr> <td style="padding: 5px;">NIHR Research Professorship</td> <td style="padding: 5px;">Concomitant primary prevention of multiple chronic diseases. £1.9M</td> </tr> <tr> <td style="padding: 5px;">NIHR Cambridge BRC</td> <td style="padding: 5px;">Data Science and Population Health theme</td> </tr> <tr> <td style="padding: 5px;">NIHR CONVALESCENCE</td> <td style="padding: 5px;">Characterisation, determinants, mechanisms and consequences of the long-term effects of COVID-19: providing the evidence base for health care services</td> </tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> <tr><td style="height: 20px;"></td><td></td></tr> </table>		HDR UK	10% secondment to the BHF Data Science Centre	NIHR Research Professorship	Concomitant primary prevention of multiple chronic diseases. £1.9M	NIHR Cambridge BRC	Data Science and Population Health theme	NIHR CONVALESCENCE	Characterisation, determinants, mechanisms and consequences of the long-term effects of COVID-19: providing the evidence base for health care services												
HDR UK	10% secondment to the BHF Data Science Centre																						
NIHR Research Professorship	Concomitant primary prevention of multiple chronic diseases. £1.9M																						
NIHR Cambridge BRC	Data Science and Population Health theme																						
NIHR CONVALESCENCE	Characterisation, determinants, mechanisms and consequences of the long-term effects of COVID-19: providing the evidence base for health care services																						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety	<input checked="" type="checkbox"/> None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
	Monitoring Board or Advisory Board	<table border="1"> <tr><td></td></tr> <tr><td></td></tr> <tr><td></td></tr> </table>				<table border="1"> <tr><td></td></tr> <tr><td></td></tr> <tr><td></td></tr> </table>			
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None							
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td></tr> <tr><td></td></tr> <tr><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td></tr> <tr><td></td></tr> <tr><td></td></tr> </table>							
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>									